



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
John M. Covert  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr.  
Michael V. Messinger  
Judith U. Kim  
Jeffrey T. Helvey  
Eldora L. Ellison

Donald R. Banowitz  
Peter A. Jackman  
Brian J. Del Buono  
Mark Fox Evans  
Vincent L. Capuano  
Elizabeth J. Haanes  
Michael D. Spedht  
Kevin W. McCabe  
Glenn J. Perry  
Edward W. Yee  
Grant E. Reed  
Virgil Lee Beaton  
Theodore A. Wood  
Joseph S. Ostroff  
Jason D. Eisenberg  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis

Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Anbar F. Khal  
Michelle K. Holoubek  
Marsha A. Rose  
Scott A. Schaller  
Lei Zhou  
W. Blake Coblentz  
James J. Pohl  
John T. Haran

Mark W. Rygiel  
Michael R. Malek\*  
Carla Ji-Eun Kim  
Doyle A. Siever\*  
Ulrike Winkler Jenks  
Paul A. Calvo  
Robert A. Schwartzman  
C. Matthew Rozier\*  
Shameek Ghose  
Randall K. Baldwin  
Registered Patent Agents\*  
Karen R. Markowicz  
Matthew J. Dowd  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Peter A. Socarras

Jeffrey K. Mills  
Danielle L. Letting  
Lori Brandes  
Steven C. Oppenheimer  
Aaron S. Lukas  
Gaurav Asthana

Of Counsel  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie  
Christopher P. Wrist

\*Admitted only in Maryland  
\*Admitted only in Virginia  
•Practice Limited to  
Federal Agencies

August 10, 2007

WRITER'S DIRECT NUMBER:  
(202) 772-8861  
INTERNET ADDRESS:  
CBOUCHEZ@SKGP.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Art Unit 1626

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application  
Application No. 10/564,511; Filed: July 3, 2006  
For: **Hetaryl-Substituted Pyrazolidindione Derivatives with Pesticidal Characteristics**  
Inventors: FISCHER *et al.*  
Our Ref: 2400.0170000/JMC/CMB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply to Restriction Requirement; and
2. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Cynthia M. Bouchez  
Attorney for Applicants  
Registration No. 47,438

VLC/CMB:krh  
Enclosures

708388\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FISCHER *et al.*

Appl. No.: 10/564,511

(U.S. National Phase of PCT/EP04/07665)

Int'l Filing Date: July 12, 2006

For: **Hetaryl-Substituted  
Pyrazolidindione Derivatives with  
Pesticidal Characteristics**

Confirmation No.: 3449

Art Unit: 1626

Examiner: Havlin, Robert H.

Atty. Docket: 2400.0170000/VLC/CMB

**Amendment and Reply to Restriction Requirement**

***Mail Stop Amendment***

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In reply to the Office Actions dated May 30, 2007 and July 11, 2007, requesting an election of one invention to prosecute in the above-referenced patent application, Applicant hereby provisionally elects to prosecute the invention of Group I, represented by claims 1-6 and 13 directed to a compound of Formula I.

The Office has also required Applicant to elect a single species for search purposes. Applicants provisionally elect compound I-3-a-1, shown on page 42, column 1, paragraph [0524] of the published application.

This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made **with** traverse.

This application is a National Phase Entry Under 35 U.S.C. § 371 and, as such, PCT Rule 13 requiring unity of invention applies. Title 37 of the Code of Federal Regulations states:

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

(1) A product and a process specially adapted for the manufacture of said product; or

(2) *A product and a process of use of said product;*

37 C.F.R. § 1.475 (b)(1)(2) (emphasis added).

The claims of Group I identified by the Office are directed to products, i.e., the compounds of claims 1-6 and 13. The claims of Group VII (claims 14 and 16) identified by the Office are directed to processes of use of the product, i.e., a method of controlling animal pests and/or unwanted vegetation comprising allowing compound of the formula (I) as claimed on claim 2 to act on the vegetation, the pests and/or their habitat. Groups I and VII therefore are related as products and processes for using such products, respectively. As noted, 37 C.F.R. § 1.475 (b)(2) states that a national stage application containing claims to a product and a process of use of said product will be considered to have unity of invention. Applicants therefore respectfully assert that the Groups I and VII share unity of invention and the Restriction Requirement is improper.

Reconsideration and withdrawal of the Restriction Requirement, and consideration and allowance of all pending claims, are respectfully requested.

Amendments to the Specification begin on page 4 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 5 of this paper.

Remarks and Arguments begin on page 35 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.